Zynex (NASDAQ:ZYXI) Updates FY 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 0.200- for the period, compared to the consensus earnings per share estimate of 0.200. The company issued revenue guidance of $200.0 million-, compared to the consensus revenue estimate of $200.5 million. Zynex also updated its Q4 guidance to at least $0.09 EPS.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Royal Bank of Canada dropped their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Zynex in a research note on Wednesday, September 4th.

Zynex Stock Up 2.8 %

Shares of NASDAQ:ZYXI traded up $0.23 during midday trading on Thursday, hitting $8.59. 151,606 shares of the company’s stock were exchanged, compared to its average volume of 173,447. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22. The stock has a 50 day moving average price of $7.96 and a 200-day moving average price of $9.23. The company has a market cap of $272.65 million, a PE ratio of 47.72 and a beta of 0.54. Zynex has a 12 month low of $7.04 and a 12 month high of $13.77.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, July 25th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). Zynex had a return on equity of 14.15% and a net margin of 3.12%. The business had revenue of $49.88 million for the quarter, compared to the consensus estimate of $51.99 million. During the same period in the previous year, the firm earned $0.09 earnings per share. The company’s revenue was up 11.0% on a year-over-year basis. On average, sell-side analysts anticipate that Zynex will post 0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Joshua R. Disbrow acquired 7,000 shares of Zynex stock in a transaction on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the transaction, the director now owns 72,000 shares of the company’s stock, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Joshua R. Disbrow acquired 7,000 shares of Zynex stock in a transaction on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the transaction, the director now owns 72,000 shares of the company’s stock, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Anna Lucsok sold 8,083 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares of the company’s stock, valued at $136,349.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 52.13% of the stock is currently owned by insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.